A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres
NCT00216528 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 527
Last updated 2010-04-27
Summary
The purpose of this study is to evaluate symptomatic remission rate in patients with schizophrenia using long acting risperidone microspheres
Conditions
Interventions
- DRUG
-
risperidone
Sponsors & Collaborators
-
Janssen Korea, Ltd., Korea
lead INDUSTRY
Principal Investigators
-
Janssen Korea, Ltd. Clinical Trial · Janssen Korea, Ltd., Korea
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-07-31
- Completion
- 2007-04-30
More Related Trials
-
A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia
NCT00249223 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder
NCT00236353 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis
NCT00216580 ·Status: COMPLETED ·Phase: PHASE3
-
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
NCT00215579 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment
NCT00526877 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
NCT00210691 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
NCT01855074 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection
NCT00236548 ·Status: COMPLETED ·Phase: PHASE3
-
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
NCT00330551 ·Status: COMPLETED ·Phase: PHASE4
-
Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)
NCT00246194 ·Status: COMPLETED
-
A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
NCT00240708 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
NCT00246259 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
NCT00216632 ·Status: COMPLETED ·Phase: PHASE4
-
Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode
NCT00216671 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone
NCT00246272 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
NCT00297388 ·Status: COMPLETED ·Phase: PHASE3
-
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
NCT00539071 ·Status: COMPLETED ·Phase: PHASE4
-
The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania
NCT00216554 ·Status: COMPLETED ·Phase: PHASE4
-
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
NCT00495118 ·Status: COMPLETED ·Phase: PHASE3
-
Switching From Consta® to Sustenna® in Patients With Schizophrenia
NCT01698216 ·Status: COMPLETED
-
A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)
NCT00294008 ·Status: COMPLETED
-
An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
NCT00992407 ·Status: COMPLETED ·Phase: PHASE4
-
Risperdal Consta and Health Care Utilization in Patients With Schizophrenia
NCT00313391 ·Status: COMPLETED ·Phase: PHASE4
-
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
NCT00314613 ·Status: TERMINATED ·Phase: PHASE4
-
A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.
NCT00261430 ·Status: COMPLETED ·Phase: PHASE4